ReviewCancers2026
Skin AllergoOncology: A Framework for Decoding the Context-Dependent Functions of the IgE-FcεRI Axis in Cutaneous Malignancies.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The immunoglobulin E (IgE)-FcεRI axis, a central mediator of allergic inflammation, plays a dual role in cutaneous tumor immunity. Epidemiological evidence presents a paradox: atopic dermatitis (AD) promotes keratinocyte carcinogenesis, yet systemic allergic responses are associated with reduced melanoma risk. This review proposes the "Skin AllergoOncology" framework to resolve this paradox. The framework defines the skin as the only human organ in which two antagonistic IgE-FcεRI programs, protective immune surveillance and chronic pro-tumor inflammation, can be spatially juxtaposed. It is organized around three analytical dimensions: IgE repertoire quality, inflammatory kinetics, and effector-cell polarization state. We critically examine the epidemiological AD-keratinocyte carcinoma association, highlighting the confounding role of immunosuppressive therapies, and review the molecular infrastructure enabling dual functional outputs, including antigen focusing by trimeric FcεRI on Langerhans cells and microenvironment-dependent mast cell polarization. We contend that the absence of direct functional evidence for protective IgE in humans represents the central question for the next decade, and we propose a five-year dual-engine roadmap to identify the human protective IgE signature. This framework informs risk-stratified surveillance, engineered IgE antibody therapy, and the long-term oncological safety assessment of anti-allergic biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.